[1] 李永杰. 局部晚期鼻咽癌放疗临床效果及预后分析[J]. 河北医学,2014,20(3):471-473. [2] Kim JS,Keam B,Heo DS,et al.The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasophayngeal Carcinoma:A Propensity Score Matching Analysis[J].Canccr Res Treat,2019,51(4):1313-1323. [3] 谢晴晴,欧阳博慧,李恩,等. γ干扰素基因多态性与鼻咽癌易感性的分析[J]. 检验医学,2018,33(6):486-490. [4] Demyashkin GA,Kastyro IV,Sidorin AV,et al.The specific immunophenotypic features of nasopharyngeal carcinoma[J]. Vestn Otorinolaringol,2018,83(5):40-44. [5] Xu T,Wu S,Yuan Y,et al.Knockdown of phosphodiesterase 4D inhibits nasopharyngeal carcinoma proliferation via the epidermal growth factor receptor signaling pathway[J]. Oncol Lett,2014,8(5):2110-2116. [6] 王蔚文. 临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010,:1362-1365. [7] 廖瑜露, 汤轶强, 舒禹先,等. 鼻咽癌调强放疗后残留及解救治疗对预后的影响[J]. 广东医学,2016,37(7):1042-1045. [8] 陈光媚,陈奕辉. 鼻咽癌患者的临床结局及其预后研究[J]. 实用癌症杂志,2014,29(2):152-153,159. [9] Shuai M,Hong J,Huang D,et al.Upregulation of circRNA_0000285 serves as a prognostic biomarker for nasopharyngeal carcinoma and is involved in radiosensitivity[J]. Oncol Lett, 2018,16(5):6495-6501. [10] 冯星来, 陈晓钟. 鼻咽癌患者治疗前外周血Th1细胞因子浓度与远期生存的关系[J]. 浙江医学, 2014,36(24):1993-1996. [11] 姜凤举, 彭裕萍, 李艳,等. Th1细胞因子水平与鼻咽癌患者预后相关性及危险因素分析[J]. 西南国防医药, 2015, 25(12):1313-1316. [12] 周美秀, 涂建仁. 鼻咽癌外周血IL-2、IL-10水平与其放化疗敏感性的相关性分析[J]. 实用癌症杂志,2017, 32(4):598-602. [13] 叶卫丰,贺敏,吴志斌. 膀胱癌患者外周血中IL-2、IFN-γ、TNF-α的表达及临床意义[J]. 临床和实验医学杂志, 2016, 15(11):1064-1067. [14] 孙恒. 血清EGF和EGFR的检测在鼻咽癌患者临床诊治中的意义[J]. 中国医药导刊,2012,14(5):875-876. [15] Dong J,Li S,Wang Q,et al.Targeted degradation of epidermal growth factor receptor in nasopharyngeal carcinoma by chimeric molecule[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2017,31(4):297-300. [16] Peng H,Tang LL,Liu X,et al.Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma[J]. Cancer Sci,2018,109(5):1609-1616. |